KRAS and lung adenocarcinoma: Thus, it has been reported that the anti-PD-1-treated subgroup of KRAS-mutant lung adenocarcinoma patients with a STK11/LKB1 co-mutation exhibits shorter PFS and OS compared to the only KRAS-mutant lung adenocarcinoma cohort or the KRAS- and TP53-mutant lung adenocarcinoma subgroup.